Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

1

Vamikibart, an anti–interleukin-6 monoclonal antibody, shows early safety in treating noninfectious uveitic macular edema.
2

The phase 1 DOVETAIL trial reported no serious drug-related adverse events or sustained intraocular pressure increases with vamikibart.
3

More than 80% of participants achieved complete resolution of intraretinal fluid by week 12, with improvements maintained at study end.
4

Corticosteroids, the standard treatment, have limitations including cataract formation and elevated intraocular pressure.
5

Ongoing phase 3 trials, MEERKAT and SANDCAT, will further assess the safety and efficacy of vamikibart for uveitic macular edema.

1